TIGIT blows up in a trial that always looked risky
Keyvibe-008 is halted for futility, an outcome that might have been foreseen in 2022.
The month ahead: August’s remaining events
Following its odronextamab knockback, Regeneron now faces a delay to linvoseltamab.
Blood cancer gene therapies enter the clinic
First-in-human trial initiations feature Interius, Umoja and Vironexis.
Claudin18.2 expression clouds Elevation's big reveal
Western data on EO-3021 fail to live up to the billing of a Chinese trial.
Nuvalent’s next battleground is HER2
NVL-330 features among the latest crop of industry projects newly into human trials.
Another vote of no-confidence in co-stimulated bispecifics
BioNTech and Genmab's acasunlimab is the latest 4-1BB project to stumble.
FDA green and red lights: July 2024
Darzalex added another string to its bow, while Kisqali’s early use has been delayed.
ALX flunks its gastric test
More bad news for CD47 as response rates in Aspen-06 wane, and the company turns to a subgroup.
Umoja and AbbVie chase Interius with in vivo Car-T
The companies hope to be as efficacious as ex vivo therapy, with convenience and safety advantages.
Is this the end for MacroGenics’ vobra-duo?
The company stops dosing in the troubled Tamarack trial, and is going quiet until ESMO.
